The rapid progression of KRAS(G12C) inhibitors from preclinical characterization to the clinic has radically changed the perception of the KRAS oncogene as an undruggable target. Here we discuss ongoing and future possibilities for developing therapies using these inhibitors in clinical settings.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
04 April 2022
A Correction to this paper has been published: https://doi.org/10.1038/s43018-022-00372-3
References
Kim, D., Xue, J. Y. & Lito, P. Cell 183, 850–859 (2020).
Li, C. et al. Science 374, https://doi.org/10.1126/science.abf1730 (2021).
Lou, K. et al. Sci. Signal. 12, eaaw9450 (2019).
Manchado, E. et al. Nature 534, 647–651 (2016).
Koga, T. et al. J. Thorac. Oncol. 16, 1321–1332 (2021).
Xue, J. Y. et al. Nature 577, 421–425 (2020).
Kruspig, B. et al. Sci. Transl. Med. 10, eaao2565 (2018).
Hong, D. S. et al. N. Engl. J. Med. 383, 1207–1217 (2020).
Skoulidis, F. et al. N. Engl. J. Med. 384, 2371–2381 (2021).
US Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug (2021).
Awad, M. M. et al. N. Engl. J. Med 384, 2382–393 (2021).
Tulpule, A. et al. Cell 184, 2649–2664.e2618 (2021).
Acknowledgements
R.R. reports funding from the Spanish Association Against Cancer (AECC; grant PROYE18012ROSE), a European Union Horizon 2020 research and innovation program, Marie Sklodowska-Curie grant agreement ELBA N 765492 and the Talent-UAB grant to support recruitment and retention of research talent at the Autonomous University of Barcelona.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Rosell, R., Aguilar, A., Pedraz, C. et al. KRAS inhibitors, approved. Nat Cancer 2, 1254–1256 (2021). https://doi.org/10.1038/s43018-021-00289-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-021-00289-3
This article is cited by
-
It’s a wrap for 2021!
Nature Cancer (2021)